

Curriculum Vitae

1. Personal information

Name: Eleni Douni
 Gender: Female
 Place of birth: Athens
 Citizenship: Greek

Academic position: Associate Professor in Animal Biotechnology
 Laboratory of Genetics, Department of Biotechnology
 Agricultural University of Athens
 75 Iera Odos, 11855, Athens Greece
 e-mail: douni@aua.gr, Tel: +30 210 5294372

Affiliation: Associate Researcher, Division of Immunology,
 Biomedical Sciences Research Center 'Alexander Fleming'
 34 Fleming, Vari, 16672, Athens, Greece.
 e-mail: douni@fleming.gr, Tel: +30 210 9656310 ext. 150

2. Education and degrees awarded

1992-1998 Ph.D. in Molecular Genetics. Thesis on "Studying the gene expression and biological role of Tumor Necrosis Factor (TNF) and its receptor p75 in transgenic mice". Department of Biology, University of Athens, & Department of Molecular Genetics-Hellenic Pasteur Institute, Athens, Greece
 1987-1991 Bachelor's degree in Biology, Department of Biology (First Class Honours), University of Athens, Greece

3. Previous work experience

1998-2000 Post Doctoral Research Associate, Molecular Genetics Laboratory, Hellenic Pasteur Institute, Athens Greece
 2000-2001 Post Doctoral Research Associate, Institute of Immunology, B.S.R.C. 'Al. Fleming'
 2001-2005 Staff Research Scientist - Assistant Professor Level, Institute of Immunology, B.S.R.C. 'Al. Fleming'
 2005-2006 Staff Research Scientist – Associate Professor Level, Institute of Immunology, B.S.R.C. 'Al. Fleming'
 2006-2011 Researcher - Assistant Professor Level at the Institute of Immunology, B.S.R.C. 'Al. Fleming'
 2012-today Associate Researcher, Division of Immunology, B.S.R.C. 'Al. Fleming'
 2012-2017 Assistant Professor, Laboratory of Genetics, Department of Biotechnology, AUA
 2017-today Associate Professor, Laboratory of Genetics, Department of Biotechnology, AUA

4. Honors, awards, fellowships

1987-1991	Undergraduate fellowships, State Scholarship for Excellence (IKY), Greek Ministry of Education
1993-1996	Ph.D. Fellowship, Bodossaki Foundation
1998-2000	Postgraduate fellowship, Molecular Genetics Laboratory, Hellenic Pasteur Institute, Athens Greece
2008-2010	National representative participating in FELASA (Federation of European Laboratory Animal Science Associations) working group for “refinement of methods for genotyping of genetically modified rodents”, 2008-2010 (www.felasa.eu/workinggroups)
2010	Award for the study “A novel genetic model of osteoporosis by overexpression of human RANKL in transgenic mice” presented by Niti A, Dacquin R, Rinotas V, Jurdic P, Douni E, at the 24 th International Mammalian Genome Conference, Heraklion 17-20 October 2010.
2010	John S. Latsis Public Benefit Foundation, Research project awarded for the Year 2010
2013	Award for the oral presentation “Novel osteoporosis models by overexpressing human RANKL in transgenic mice” by Rinotas V, Papadaki M, Dacquin R, Bonnet N, Jurdic P, Ferrari S, Douni E, at the 64 th Congress of the Hellenic Society of Biochemistry and Molecular Biology, 6-8 December 2013.
2014	Hellenic Ministry of Education, GSRT, grant "ARISTEIA II"
2017	Co-Founder and Executive Board of the International Bone Marrow Adiposity Society (2017-2020) (http://bma-society.org/)
2018	Member of the "Basic Science Practice Action Group, Policies & Consensus Committee" assigned by the European Calcified Tissue Society (http://ectsoc.org/about-ects/policies-consensus-committee)
2018	Award in recognition of an excellent research contribution. 7th International Conference on Osteoimmunology "Interactions of the Immune and Skeletal Systems", 3-8 June 2018, Chania.
2019-2022	Elected Board Member of the Institute Scientific Committee of the Institute for Bioinnovation, Biomedical Sciences Research Center “Alexander Fleming”.
2019-2024	Board Member of the Educational Center for Life-Long Learning of the Agricultural University of Athens.
2019-2023	Elected Member of the Dean’s Committee of the School of Applied Biology and Biotechnology of the Agricultural University of Athens.
2020	Member of the Scientific Board of the International Bone Marrow Adiposity Society (2020-2023).
2022	Organization of the “7 th International Meeting on Bone Marrow Adiposity”, Greece.

5.1 Areas of Research Interests

- Functional Genetics for the identification of novel disease targets in mammals
- Analysis of the pathophysiological role of RANKL in osteoporosis, bone marrow adiposity and breast cancer using transgenic mice overexpressing human RANKL
- Development and biochemical characterization of novel RANKL inhibitors, evaluation in cellular assays and in our proprietary transgenic mouse model of RANKL-mediated osteoporosis
- Study of the pathogenic role of mitochondrial proteins SLC25A46 and DnaJC11 in neurodegenerative diseases

5.2 Technical Expertise

- Generation and characterization of transgenic and knockout mice
- ENU mutagenesis and screening of novel phenotypes
- Genome- wide genetic analysis using polymorphic markers (SNPs & SSLPs).
- Advanced Molecular Biology practices
- Biochemistry, immunoprecipitation, production of recombinant proteins
- Mitochondria isolation and analysis
- Immunological assays
- Histopathological analysis of mouse tissues including CNS
- Tissue culture practices: Stable and transient transfection of immortalized cell lines; isolation and culture of primary cells
- Proteomic analysis

6. Research funding

- Agency/No:* Hellenic Ministry for Development – ΕΠΑΝ 340
Duration: 2005-2008
Type: Excellence in the Research Institutes
Title: **Research infrastructures of the Institute of Immunology of the BSRC Fleming**
Role: Co-Investigator
- Agency/No:* Hellenic Ministry for Development – 04AKMON72
Duration: 2005-2008
Type: AKMON (PI: Dr G. Kollias)
Title: **Enhancement of services in transgenesis, on disease models and macromolecular analysis from laboratories of the BSRC Fleming**
Role: Co-Investigator
- Agency/No:* European Commission NoE – LSHG-CT-2005-005203
Duration: 2005-2009
Type: Network of Excellence (24 participating labs, PI: Dr G. Kollias)
Title: **Integrated functional genomics in mutant mouse models as tools to investigate the complexity of human immunological disease (MUGEN)**
Role: Co-Investigator
- Agency/No:* John S. Latsis Foundation *Duration:* 2010
Type: Research project awarded for the Year 2010
Title: **Generation and analysis of a novel genetic model of osteoporosis in transgenic mice overexpressing human RANKL**
Role: Coordinator
- Agency/No:* Hellenic Ministry of Education *Duration:* 2011-2014
Type: National action “Cooperation” (6 part. institutions, PI: Dr G. Kollias)
Title: **From Targets to Leads: Innovative therapeutics for arthritis**
Role: Co-Investigator
- Agency/No:* AMGEN, USA *Duration:* 2012-2013
Type: Funded research protocol (3 participating institutions, PI: E. Douni)

Title: Rescue of modeled osteoporosis with administration of anti-RANKL therapies in transgenic mice overexpressing human RANKL

Role: Coordinator

Agency/No: Hellenic Ministry of Education *Duration:* 2012-2015

Type: “Thalis” grant (8 participating institutions, PI: Prof. S. Zaoutsos)

Title: **Nanostructured geopolymers and calcium phosphate based biocements and implants**

Role: Co-Investigator

Agency/No: Hellenic Ministry of Education *Duration:* 2012-2015

Type: “Thalis” grant (7 participating institutions, PI: Prof. A. Plaitakis)

Title: **Mitochondrial Dysfunction in Neurodegenerative Disorders**

Role: Co-Investigator

Agency/No: European Commission *Duration:* 2012-2016

Type: ITN grant (11 participating institutions, PI: Prof. T. Kamradt)

Title: **OSTEOIMMUNE – Unraveling the Interactions between the Immune System and Bone**

Role: Co-Investigator

Agency/No: GSRT, Hellenic Ministry of Education *Duration:* 2014-2015

Type: ARISTEIA II grant (Excellence)

Title: **DnaJmito – Role of DNAJC in mitochondrial cristae structure and modeled neuromuscular disease**

Role: Coordinator

Agency/No: GSRT, Hellenic Ministry of Education *Duration:* 2018-2021

Type: RESEARCH – CREATE – INNOVATE grant

Title: **Development of an innovative mouse model of RANKL-induced breast cancer and integration of cutting-edge technologies for the establishment of a preclinical platform for drug evaluation**

Role: Coordinator

Agency/No: European Commission *Duration:* 2019-2024

Type: COST ACTION

Title: **GENOMICS OF MUSCULOSKELETAL TRAITS TRANSLATIONAL NETWORK (GEMSTONE, CA18139)**

Role: Co-Investigator

Agency/No: Ministry of Development and Investments *Duration:* 2019-2021

Type: Support of New Researchers

Title: **Study of the mitochondrial protein SLC25A46 in the pathophysiology of neurodegenerative diseases in a genetic mouse model - MIS 5048544**

Role: Coordinator

7. Merits in teaching

2006-today Animal Biotechnology (undergraduate students, 7th sem., AUA)

2012-today Genetics (undergraduate students, 3rd semester, AUA)

2015-2019	Genetics of Model Organisms (undergraduate students, 8 th semester)
2016-today	Immunology (undergraduate students, 6 th sem., AUA)
2001-2009	Invited lecturer at the post graduate Master course program "Methodology of Research in Basic Medical Sciences", Medical School, University of Patras
2009-2020	Invited lecturer at the post graduate Master course program "Applied Physiology", Medical School, University of Athens
2010-2015	Invited lecturer at the post graduate Master course program "Introduction of Research Methodology", Medical School, University of Athens
2012-2014	Lecturer at the post graduate Master course program "Biotechnology and Applications in Agricultural Sciences", Department of Agricultural Biotechnology, AUA
2014-2020	Lecturer at the post graduate Master course program "System Biology", Department of Agricultural Biotechnology, AUA
2015-2018	Invited lecturer at the post graduate Master course program "Current topics in Biosciences", Department of Biology, Aristotle University of Thessaloniki
2016-2020	Invited lecturer at the post graduate Master course program "Molecular Biomedicine", Medical School, University of Athens in collaboration with B.S.R.C. "Al. Fleming"

8. Supervision

- Diploma thesis supervision of 26 undergraduate students from the Department of Biotechnology, AUA
- Supervisor of 8 Master Theses
- Supervisor of 9 Ph.D. Theses, 6 completed (Vagelis Rinotas/2014, Fotis Ioakeimidis/2014, Alexandra Niti/2015, Maria-Eirini Terzenidou/2017, Maria Papadaki/2019, Foteini Violitzi/2019) and 3 in progress (Anthi Kolokotroni, Vassiliki-Iris Perivolidi, Evi Gkikopoulou)

8.1 List of Undergraduate Theses

- Fotis Ioakeimidis, Department of Biotechnology, Agricultural University of Athens, title of undergraduate thesis: "Studying the role of the cytoplasmic region of Tumor Necrosis Factor (TNF) in transgenic mice", 3-11/2008.
- Alexandros Karakostas, Department of Biotechnology, Agricultural University of Athens, title of undergraduate thesis: "Genetic analysis of a new mouse model of ataxia", 3-11/2008.
- Toshimi Kano, Department of Biotechnology, Agricultural University of Athens, title of undergraduate thesis: "Studying the expression of SLC25 in a mouse model of recessive neurological disease", 3-11/2012.
- Foteini Violitzi, Department of Biotechnology, Agricultural University of Athens, title of undergraduate thesis: "Inhibition of trimerization of BAFF through directed mutagenesis", 2-9/2012.
- Marios-Evagelos Boyongo, Department of Biotechnology, Agricultural University of Athens, title of undergraduate thesis: "Study of DNAJC11 protein interactions", 3-11/2014.
- Niki Chalkidi, Department of Biotechnology, Agricultural University of Athens, title of undergraduate thesis: "Evaluation of small molecule inhibitors of RANKL in cell assays" 3-11/2014.
- Theodora Manolakou, Department of Biotechnology, Agricultural University of Athens, title of undergraduate thesis: "Inactivation of the DnaJC11 gene with CRISPR/CAS9 in a cell line", 3-9/2016.

- Anastasia Rigou, Department of Biotechnology, Agricultural University of Athens, title of undergraduate thesis: "Characterization of DnaJC11-FLAG transgenic mice", 3-9/2016.
- Emmanouil Siniorakis, Department of Biotechnology, Agricultural University of Athens, title of undergraduate thesis: "Study of bone marrow adipogenesis in transgenic models of osteoporosis", 3-10/2016.
- Cristina Fracassi, Department of Biosciences and Biotechnology, University of Camerino, Italy, title of undergraduate thesis: "Approaches for analysis of Bone Marrow Adiposity in a mouse model of osteoporosis", 3-6/2016.
- Vassilios Bakogiannis, Department of Biotechnology, Agricultural University of Athens, title of undergraduate thesis: "Effect of Tumor Necrosis Factor (TNF) deletion in TgRANKL transgenic models of osteoporosis", 11/2016 -7/2017.
- Vassiliki-Iris Perivolidi, Department of Biotechnology, Agricultural University of Athens, title of undergraduate thesis: "Detection of DNAJC11 protein interactions in transgenic DNAJC11-FLAG mice", 3-8/2017.
- Efthimios Tzortzis, Department of Biotechnology, Agricultural University of Athens, title of undergraduate thesis: "Study of bone marrow adipogenesis mechanisms in the transgenic osteoporosis model Tg5519", 2-12/2017.
- Panagiota Siatra, Department of Biotechnology, Agricultural University of Athens, title of undergraduate thesis: "Study of bone marrow adipogenesis formation in the transgenic osteoporosis model Tg5516", 4-12/2017.
- Antigone Kontou, Department of Biosciences and Biotechnology, University of Camerino, Italy, title of undergraduate thesis: "Differentiation potential of mesenchymal stromal cells in TgRANKL mouse models of osteoporosis", 1-6/2017.
- Christos Mantzoros, Department of Biotechnology, Agricultural University of Athens, title of undergraduate thesis: "Mapping of the SLC25A46 protein regions involved in mitochondrial localization", 2-10/2018.
- Evi Gkikopoulou, Department of Biotechnology, Agricultural University of Athens, title of undergraduate thesis: "Analysis of the mammary gland of TgRANKL transgenic mice", 2-10/2018.
- Georgia Daraki, Department of Biotechnology, Agricultural University of Athens, title of undergraduate thesis: "Generation of recombinant plasmids for the expression of the chimeric protein SLC25A46-FLAG in mammalian cells", 2-10/2018.
- Panagiotis Nikolaou, Department of Biotechnology, Agricultural University of Athens, title of undergraduate thesis: "Comparative analysis of femurs from TgRANKL transgenic mouse models of osteoporosis", 2-10/2018.
- Konstantinos Kritikos, Department of Biotechnology, Agricultural University of Athens, title of undergraduate thesis: "Analysis of mesenchymal bone marrow cells from transgenic models of osteoporosis", 2-10/2018.
- Eirini Efstathiou, Department of Biotechnology, Agricultural University of Athens, title of undergraduate thesis: "Molecular and imaging analysis of the mammary gland from the transgenic mouse model Tg5519", 2-10/2019.
- Aristofanis Stavrou, Department of Biotechnology, Agricultural University of Athens, title of undergraduate thesis: "Generation of recombinant plasmids for the human mutations of SLC25A46 gene", 2-10/2019.

- Konstantina-Maria Nikolaou, Department of Biotechnology, Agricultural University of Athens, title of undergraduate thesis: "Analysis of the skeletal system of mouse models with mitochondrial neurological diseases", 2-10/2019.
- Athanasios Rentis, Department of Biotechnology, Agricultural University of Athens, title of undergraduate thesis: "Regulation of the mammary glands from TgRANKL transgenic mice with progesterone", 2-10/2019.
- Ioannis Ntounias, Department of Biotechnology, Agricultural University of Athens, title of undergraduate thesis: "Generation of recombinant plasmids for the human SLC25A46 gene", 2-10/2019.
- Apostolos Papadopoulos, Department of Biotechnology, Agricultural University of Athens, title of undergraduate thesis: "Analysis of the musculoskeletal system of TgRANKL transgenic mice", 2-12/2019.

8.2 List of MSc students

- Alexandra Niti, Medical School, University of Athens, MSc program "Metabolic Bone Diseases", title of MSc thesis: "Studying the overexpression of RANKL in transgenic mice: Development of a novel osteoporosis model", 2-10/2009.
- Alexandros Karakostas, Department of Biotechnology, Agricultural University of Athens, MSc program "Biotechnology and applications in Agriculture", title of MSc thesis: "Detailed genetic analysis in mouse chromosome 18 for the identification of a novel pathogenetic target causing a lethal neurological phenotype", 2-11/2010.
- Toshimi Kano, Department of Biotechnology, Agricultural University of Athens, MSc program "Biotechnology and applications in Agriculture", title of MSc thesis: "Molecular and Genetic study of human Slc25a46 gene in transgenic mice", 3-9/2013.
- Foteini Violitzi, Department of Biotechnology, Agricultural University of Athens, MSc program "Biotechnology and applications in Agriculture", title of MSc thesis: "Evaluation of novel RANKL inhibitors for the identification of novel anti-osteoporotic drugs", 10/2012-11/2013.
- Eirini Gialitaki, Department of Biotechnology, Agricultural University of Athens, MSc program "System Biology", title of MSc thesis: "Detection of DNAJC11 gene polymorphisms in Amyotrophic Lateral Sclerosis patients", 5-12/2015.
- Ippokratis Lygizos, Department of Biotechnology, Agricultural University of Athens, MSc program "System Biology", title of MSc thesis: "Study of SLC25A46 deletion in the mouse nervous system", 12/2016-10/2017.
- Polina Pantelidou, Department of Pharmacy, University of Athens, MSc program "Nanomedicine", title of MSc thesis: "Investigating the role of exosomes in osteoporotic models", 12/2018-8/2019.
- Elisavet Ioannidou, Medical School, University of Athens, MSc program "Molecular Biomedicine", title of MSc thesis: "Analysis of the transcriptome in modeled osteoporosis", 9/2020-6/2021.

8.3 List of PhD students

- Fotis Ioakeimidis, School of Biology, Aristotle University of Thessaloniki, PhD thesis title: "Study of pathogenic mechanisms in a novel mouse model of autosomal recessive neuromuscular disease with phenotypic, genetic and molecular analysis", 2010-2014. Supervisor Professor: A. Lazou.

- Vagelis Rinotas, Department of Biotechnology, Agricultural University of Athens, PhD thesis title: "Study of RANKL-mediated pathogenic mechanisms in animal models and new therapeutic approaches", 2011-2014. Supervisor Professor: E Douni.
 - Niti Alexandra, Medical School, University of Athens, PhD thesis title: "Studying the pathogenic role of RANKL in animal models", 2010-2015. Supervisor Professor: M Koutsilieris.
 - Maria-Eirini Terzenidou, Department of Biotechnology, Agricultural University of Athens, PhD thesis title: "Studying the pathogenic role of the mitochondrial carrier SLC25 in a genetic model of neurological disease in mice", 2012-2017. Supervisor Professor: E Douni.
 - Maria Papadaki, Department of Biotechnology, Agricultural University of Athens, PhD thesis title: "Studying the role of RANKL in osteoimmune interactions using transgenic mouse models of bone resorption", 2013-2018. Supervisor Professor: E Douni.
 - Foteini Violitzi, Department of Biotechnology, Agricultural University of Athens, PhD thesis title: "Study of the pathophysiological role of DnaJC11 gene in a mouse model of neuromuscular disease", 2014-2018. Supervisor Professor: E Douni.
 - Anthi Kolokotroni, Department of Biotechnology, Agricultural University of Athens, PhD thesis title: "Study of the pathophysiological role of RANKL protein in the mammary gland of transgenic mice", 2017-ongoing. Supervisor Professor: E Douni.
 - Vassiliki-Iris Perivolidi, Department of Biotechnology, Agricultural University of Athens, PhD thesis title "Studying pathophysiological mechanisms in modeled SLC25A46-mediated neurological disease in mice through Molecular Genetics and Proteomic approaches", 2018-ongoing. Supervisor Professor: E Douni.
 - Evi Gkikopoulou, Department of Biotechnology, Agricultural University of Athens, PhD thesis title "RANKL and carcinogenic mechanisms in transgenic mice" 2019-ongoing. Supervisor Professor: E Douni.
-

9. Other academic merits

9.1 Reviewer for International Scientific Journals: Annals of the Rheumatic Diseases, Arthritis Research & Therapy, Clinical and Developmental Immunology, European Journal of Immunology, European Journal of Medicinal Chemistry, FEBS Journal, Frontiers in Cell and Developmental Biology, Frontiers in Endocrinology, Frontiers in Immunology, Frontiers in Pharmacology, International Journal of Molecular Sciences, ISRN Rheumatology, Journal of Clinical Investigation, Journal of Experimental Medicine, Journal of Immunology, Journal of Immunology Research, Journal of Inflammation Research, Laboratory Investigation, Pharmacology, Plos One, Stem Cells

9.2 Grant Evaluator for International Funding Bodies

- GSRT, Hellenic Ministry of Education
- State Scholarships Foundation (IKY)
- Hellenic Foundation for Research and Innovation (HFRI)
- European Calcified Tissue Society
- Institut Pasteur France, Actions Concertées Inter-Pasteuriennes
- GIS-IBiSA French infrastructures
- Research Foundation – Flanders Belgium (FWO)

9.3 Member of Scientific Societies

- Co-Founder and Executive Board of the International Bone Marrow Adiposity Society (2017-2020) (<http://bma-society.org/>)
- European Calcified Tissue Society
- American Society for Bone and Mineral Research
- Hellenic Society for the Study of Bone Metabolism
- Hellenic Society of Biochemistry and Molecular Biology
- Hellenic Society of Biosciences
- Hellenic Society of Biomaterials

9.4 Organization of conferences

- Member of the Organizing and Examination Committee of the annual course «International Course on Laboratory Animal Science», 2007-2011, B.S.R.C. “Al. Fleming”, Athens
- Organizing member of the International «Workshop on Mouse Immune Phenotyping», 6-8 October 2009, Athens
- Member of the Organizing Committee of the 2nd Conference of Agricultural Biotechnology, October 2012, Athens
- Member of the Organizing Committee of the 66th Conference of the Hellenic Society of Biochemistry and Molecular Biology, 11-13 December 2015, Athens
- Member of the National Advisory Committee of the 28th Annual Conference of the European Society for Biomaterials, 4-8 September 2017, Athens
- Member of the Scientific Committee of the European Calcified Tissue Society Conference 2020
- Organizer of the “7th International Meeting on Bone Marrow Adiposity”, 2022, Greece.

Invited speaker: >50 talks (International conferences, Universities/Research Institutes, Companies).

Presentations in Scientific Conferences: >100

Peer-reviewed Publications in International Scientific Journals: 41

Citations till September 2020: 2564

h-index: 21

Total Impact Factor: 227.077

Average Impact Factor: 6.679

10.1 Publications

1. Grell M, **Douni E**, Wajant H, Lohden M, Clauss M, Maxeiner B, Georgopoulos S, Lesslauer W, Kollias G, Pfizenmaier K, Scheurich P. (1995). The transmembrane form of Tumour Necrosis Factor (TNF) is the prime activating ligand of the 80 kDa TNF receptor. *Cell*; 83, 793-802.
2. **Douni E**, Akassoglou K, Alexopoulou L, Georgopoulos S, Haralambous S, Hill S, Kassiotis G, Kontoyiannis D, Pasparakis M, Plows D, Probert L, Kollias G. (1995). Transgenic and knockout analysis of the role of TNF in immune regulation and disease pathogenesis. *Journal of Inflammation*; 47, 27-38.
3. Probert L, Akassoglou K, Alexopoulou L, **Douni E**, Haralambous S, Hill S, Kassiotis G, Kontoyiannis D, Pasparakis M, Plows D, Kollias G. (1996). Dissection of the pathologies

- induced by transmembrane and wild-type tumour necrosis factor in transgenic mice. **Journal of Leukocyte Biology**; 59, 518-525.
4. Pasparakis M, Alexopoulou L, **Douni E**, Kollias G. (1996). Tumour necrosis factors in immune regulation: everything that's interesting is ... new! **Cytokine and Growth Factor Reviews**; 7, 223-229.
 5. Kusters S, Tiegs G, Alexopoulou L, Pasparakis M, **Douni E**, Kunstle G, Bluethmann H, Wendel A, Pfizenmaier K, Kollias G, Grell M. (1997). In vivo evidence for a functional role of both tumor necrosis factor (TNF) receptors and transmembrane TNF in experimental hepatitis. **European Journal of Immunology**; 27, 2870-2875.
 6. **Douni E**, Kollias G. (1998). A critical role of the p75TNF-R in organ inflammation independent of TNF, LT α or the p55 TNF-R. **Journal of Experimental Medicine**; 188, 1343-1352.
 7. Kollias G, **Douni E**, Kassiotis G, Kontoyiannis D. (1999). On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. **Immunological Reviews**; 169, 175-194.
 8. Kollias G, **Douni E**, Kassiotis G, Kontoyiannis D. (1999). The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. **Annals of the Rheumatic Diseases**; 58, 132-139.
 9. Holtmann M, **Douni E**, Schutz M, Mudter J, Lehr H, Gerspach J, Scheurich P, Galle P, Kollias G, Neurath M. (2002). TNF-R2 is upregulated on lamina propria mononuclear cells in Crohn's disease and promotes experimental colitis in vivo. **European Journal of Immunology**; 32:3142-3151.
 10. Akassoglou K, **Douni E**, Bauer J, Lassmann H, Kollias G, Probert L. (2003). Exclusive tumor necrosis factor (TNF) signaling by the p75TNF receptor triggers inflammatory ischemia in the CNS of transgenic mice. **PNAS**; 100:709-714.
 11. **Douni E**, Sfrikakis P, Haralambous S, Fernandez P, Kollias G. (2004). Attenuation of inflammatory polyarthritis in TNF transgenic mice by diacerein: comparative analysis with dexamethasone, methotrexate and anti-TNF protocols. **Arthritis Research & Therapy**; 6(1):R65-R72.
 12. Maung-Maung T, **Douni E**, Aidinis V, Kollias G, Kodama K, Sato K, Satish RL, Mahendran R, Gopalakrishnakone P. (2004). Effect of Phospholipase A2 Inhibitory Peptide on Inflammatory Arthritis in a TNF Transgenic Mouse Model: A Time Course Ultrastructural Study. **Arthritis Research & Therapy**; 6(3):R282-94.
 13. Alexopoulou L, Kranidioti K, Xanthoulea S, Denis M, Kotanidou A, **Douni E**, Blackshear PJ, Kontoyiannis DL, Kollias G. (2006). Transmembrane TNF protects mutant mice against intracellular bacterial infections, chronic inflammation and autoimmunity. **European Journal of Immunology**; 36(10):2768-80.
 14. Aidinis V, Chandras C, Manoloukos M, Thanassopoulou A, Kranidioti K, Armaka M, **Douni E**, Kontoyiannis DL, Zouberakis M, Kollias G; MUGEN NoE consortium. (2008). MUGEN mouse database; animal models of human immunological diseases. **Nucleic Acids Research**; 36: D1048-54.
 15. Thwin MM, **Douni E**, Arjunan P, Kollias G, Kumar PV, Gopalakrishnakone P. (2009). Suppressive effect of secretory phospholipase A2 inhibitory peptide on IL-1 β -induced matrix metalloproteinases production in rheumatoid synovial fibroblasts, and its antiarthritic activity in hTNFtg mice. **Arthritis Research & Therapy**; 11:R138. doi: 10.1186/ar2810.
 16. Morgan H, Beck T, Blake A, Gates H, Adams N, Debouzy G, Leblanc S, Lengger C, Maier H, Melvin D, Meziane H, Richardson D, Wells S, White J, Wood J; **EUMODIC Consortium**, de

- Angelis MH, Brown SD, Hancock JM, Mallon AM. (2010). EuroPhenome: a repository for high-throughput mouse phenotyping data. *Nucleic Acids Res*; 38:D577-85. doi: 10.1093/nar/gkp1007.
17. **Douni E**, Rintotas V, Makrinou E, Zwerina J, Penninger JM, Eliopoulos E, Schett G, Kollias G. (2012). A RANKL G278R mutation causing osteopetrosis identifies a functional amino acid essential for trimer assembly in RANKL and TNF. *Human Molecular Genetics*; 21(4):784-98. doi: 10.1093/hmg/ddr510.
 18. Papaneophytou CP, Mettou AK, Rintotas V, **Douni E**, Kondopidis GA. (2013). Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF- α /SPD304 Study. *ACS Medicinal Chemistry Letters*; 4 (1):137–141. doi: 10.1021/ml300380h.
 19. Bonaparte D, Cinelli P, **Douni E**, Héroult Y, Maas A, Pakarinen P, Poutanen M, Lafuente MS, Scavizzi F. (2013). FELASA guidelines for the refinement of methods for genotyping genetically-modified rodents: a report of the Federation of European Laboratory Animal Science Associations Working Group. *Laboratory Animals*; 47(3):134-45.
 20. Papaneophytou CP, Rintotas V, **Douni E**, Kontopidis G. (2013). A statistical approach for optimization of RANKL overexpression in Escherichia coli: Purification and characterization of the protein. *Protein Expression and Purification*; 90(1):9-19. doi: 10.1016/j.pep.2013.04.005.
 21. Zoi OG, Thireou TN, Rintotas VE, Tsoungas PG, Eliopoulos EE, **Douni EK**, Labrou NE, Clonis YD. (2013). Designer Xanthone: An Inhibitor Scaffold for MDR-Involved Human Glutathione Transferase Isoenzyme A1-1. *Journal of Biomolecular Screening*; 18(9):1092-102. doi: 10.1177/1087057113492335.
 22. Rintotas V, Niti A, Dacquin R, Bonnet N, Stolina M, Han CY, Kostenuik P, Jurdic P, Ferrari S, **Douni E**. (2014). Novel genetic models of osteoporosis by overexpression of human RANKL in transgenic mice. *Journal of Bone and Mineral Research*; 29(5):1158-69. doi: 10.1002/jbmr.2112.
 23. Perperopoulou FD, Tsoungas PG, Thireou TN, Rintotas VE, **Douni EK**, Eliopoulos EE, Labrou NE, Clonis YD. (2014). 2,2'-Dihydroxybenzophenones and their carbonyl N-analogues as inhibitor scaffolds for MDR-involved human glutathione transferase isoenzyme A1-1. *Bioorganic and Medicinal Chemistry*; 22(15):3957-70. doi: 10.1016/j.bmc.2014.06.007.
 24. Ioakeimidis F, Ott C, Kozjak-Pavlovic V, Violitzi F, Rintotas V, Makrinou E, Eliopoulos E, Fasseas C, Kollias G, **Douni E**. (2014). A splicing mutation in the novel mitochondrial protein DNAJC11 causes motor neuron pathology associated with cristae disorganization, and lymphoid abnormalities in mice. *PLoS One*; 9(8):e104237. doi: 10.1371/journal.pone.0104237.
 25. Alexiou P, Papakyriakou A, Ntougkos E, Papaneophytou CP, Liepouri F, Mettou A, Katsoulis I, Maranti A, Tsiliouka K, Strongilos A, Chaitidou S, **Douni E**, Kontopidis G, Kollias G, Couladouros E, Eliopoulos E. (2014). Rationally designed less toxic SPD-304 analogs and preliminary evaluation of their TNF inhibitory effects. *Archiv der Pharmazie*; 347(11):798-805. doi: 10.1002/ardp.201400198.
 26. Papaneophytou C, Alexiou P, Papakyriakou A, Ntougkos E, Tsiliouka K, Maranti A, Liepouri F, Strongilos A, Mettou A, Couladouros E, Eliopoulos E, **Douni E**, Kollias G, Kontopidis G. (2015). Synthesis and biological evaluation of potential small molecule inhibitors of tumor necrosis factor. *Medicinal Chemistry Communications*; 6: 1196-1209. doi.org/10.1039/C5MD00023H
 27. Llop-Guevara A, Porras M, Cendón C, Di Ceglie I, Siracusa F, Madarena F, Rintotas V, Gómez L, van Lent PL, **Douni E**, Chang HD, Kamradt T, Román J. (2015). Simultaneous inhibition of JAK and SYK kinases ameliorates chronic and destructive arthritis in mice. *Arthritis Research & Therapy*; 17:356. doi: 10.1186/s13075-015-0866-0.

28. Agas D, Marchetti L, **Douni E**, Sabbieti MG. (2015). The unbearable lightness of bone marrow homeostasis. *Cytokine & Growth Factor Reviews*; 26(3):347-59. doi: 10.1016/j.cytogfr.2014.12.004.
29. Terzenidou ME, Segklia A, Kano T, Papastefanaki F, Karakostas A, Charalambous M, Ioakeimidis F, Papadaki M, Kloukina I, Chrysanthou-Piterou M, Samiotaki M, Panayotou G, Matsas R, **Douni E**. (2017). Novel insights into SLC25A46-related pathologies in a genetic mouse model. *PLOS Genetics*; 13(4): e1006656. doi: 10.1371/journal.pgen.1006656.
30. Melagraki G, Ntougkos E, Rinotas V, Papaneophytou C, Leonis G, Mavromoustakos T, Kontopidis G, **Douni E**, Afantitis A, Kollias G. (2017). Cheminformatics-aided discovery of small-molecule Protein-Protein Interaction (PPI) dual inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF- κ B Ligand (RANKL). *PLOS Computational Biology*; 13(4): e1005372. doi: 10.1371/journal.pcbi.1005372.
31. Melagraki G, Ntougkos E, Papadopoulou D, Rinotas V, Leonis G, **Douni E**, Afantitis A, Kollias G. (2018). In Silico Discovery of Plant-Origin Natural Product Inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF- κ B Ligand (RANKL). *Frontiers in Pharmacology*; 9:800. doi: 10.3389/fphar.2018.00800.
32. Rinotas V, **Douni E**. (2018). Molecular Interaction of BMAT with Bone. *Current Molecular Biology Reports*; 4(2):34–40. DOI: 10.1007/s40610-018-0093-y
33. Melagraki G, Leonis G, Ntougkos E, Rinotas V, Papaneophytou C, Mavromoustakos T, Kontopidis G, **Douni E**, Kolias G, Afantitis A. (2018). Current Status and Future Prospects of Small-molecule Protein-protein Interaction (PPI) Inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF- κ B Ligand (RANKL). *Current Topics in Medicinal Chemistry*; 18(8):661-673. doi: 10.2174/1568026618666180607084430.
34. Plaitakis A, Kotzamani D, Petraki Z, Delidaki M, Rinotas V, Zaganas I, **Douni E**, Sidiropoulou K, Spanaki C. (2019). Transgenic Mice Carrying GLUD2 as a Tool for Studying the Expressional and the Functional Adaptation of this Positive Selected Gene in Human Brain Evolution. *Neurochemical Research*; 44(1):154-169. doi: 10.1007/s11064-018-2546-3.
35. Anastasilakis AD, Polyzos SA, Makras P, **Douni E**, Mantzoros CS. (2019). Irisin: good or bad for the bone? A new path forward after the reported discovery of irisin receptor? *Metabolism*; 93:100-102. doi: 10.1016/j.metabol.2019.01.013.
36. Papadaki M, Rinotas V, Violitzi F, Thireou T, Panayotou G, Samiotaki M, **Douni E**. (2019). New insights for RANKL as a proinflammatory modulator in modeled inflammatory arthritis. *Frontiers in Immunology*; 10:97. doi: 10.3389/fimmu.2019.00097.
37. Bonnet N, Bourgoin L, Biver E, **Douni E**, Ferrari S. (2019). RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass. *Journal of Clinical Investigation*; 129(8):3214-3223. doi: 10.1172/JCI125915.
38. Violitzi F, Perivolidi VI, Thireou T, Grivas I, Haralambous S, Samiotaki M, Panayotou G, **Douni E**. (2019). Mapping Interactome Networks of DNAJC11, a Novel Mitochondrial Protein Causing Neuromuscular Pathology in Mice. *Journal of Proteome Research*; doi: 10.1021/acs.jproteome.9b00338.
39. Bravenboer N, Bredella MA, Chauveau C, Corsi A, **Douni E**, Ferris WF, Riminucci M, Robey PG, Rojas-Sutterlin S, Rosen C, Schulz TJ, Cawthorn WP. (2020). Standardised Nomenclature,

Abbreviations, and Units for the Study of Bone Marrow Adiposity: Report of the Nomenclature Working Group of the International Bone Marrow Adiposity Society. *Frontiers in Endocrinology*; 10:923. doi: 10.3389/fendo.2019.00923.

40. Tratwal J, Labella R, Bravenboer N, Kerckhofs G, **Douni E**, Scheller EL, Badr S, Karampinos DC, Beck-Cormier S, Palmisano B, Poloni A, Moreno-Aliaga MJ, Fretz J, Rodeheffer MS, Boroumand P, Rosen CJ, Horowitz MC, van der Eerden BCJ, Veldhuis-Vlug AG, Naveiras O. (2020). Reporting Guidelines, Review of Methodological Standards, and Challenges Toward Harmonization in Bone Marrow Adiposity Research. Report of the Methodologies Working Group of the International Bone Marrow Adiposity Society. *Frontiers in Endocrinology*; 11:65. doi: 10.3389/fendo.2020.00065.
41. Rinotas V, Papakyriakou A, Violitzi F, Papaneophytou C, Ouzouni MD, Alexiou P, Strongilos A, Couladouros E, Kontopidis G, Eliopoulos E, **Douni E**. (2020). Discovery of Small-Molecule Inhibitors of Receptor Activator of Nuclear Factor- κ B Ligand with a Superior Therapeutic Index. *Journal of Medicinal Chemistry*; doi: 10.1021/acs.jmedchem.0c01316.

10.2 Book chapters

1. Kollias G, Kontoyiannis D, **Douni E**, Kassiotis G. (2002). The role of TNF/TNFR in organ-specific and systemic autoimmunity: implications for the design of optimized `anti-TNF` therapies. In *Curr. Dir. Autoimmun.*: Signal transduction pathways in autoimmunity, Eds. A. Theofilopoulos, Karger Press; 5:30-50.
2. **Douni E**, Alexiou M, Kollias G. (2004). Genetic engineering in the mouse: Tuning TNF/TNFR expression. In *Methods in Molecular Medicine*: Tumor Necrosis Factor. Eds A. Corti and P. Ghezzi. Humana Press Inc; 98: p139-171.
3. **Douni E**, Armaka M, Kontoyiannis DL, Kollias G. (2007). Functional genetic and genomic analysis of modeled arthritis. In *Adv Exp Med Biol.*: Osteoimmunology. Interactions of the Immune and Skeletal Systems. Ed Y Choi, Springer; 602:33-42.

10.3 Meeting reports

Douni E. (2014). Meeting report from the 5th International Conference on Osteoimmunology 2014. IBMS BoneKEy 11, Article number: 619 (2014) | doi:10.1038/bonekey.2014.114

11. Abstracts in International Conferences (from 2004)

1. **Douni E**, Sekara E, Kamber M, Kontoyiannis D, Kollias G. (2004). Sensitized ENU mutagenesis screen in animal models of chronic inflammatory diseases. *Eumorphia annual meeting*. 5-7 October, London.
2. Faggioni R, Babcook J, **Douni E**, Kang J, Schneider A, Manchulenko K, Rathanaswami P, Kollias G (2004). ABX10131: a fully human anti-human TNF mAb generated using XenoMouse[®] and XenoMax[™] technologies. *ICS and ICICR 5th Joint International Meeting*, October.

3. **Douni E**, Makrinou E, Mermelekas G, Giannakas N, Kollias G. (2005). A sensitized ENU mutagenesis screen for genetic modifiers of Rheumatoid Arthritis and Inflammatory Bowel Disease. *19th International Mouse Genome Conference*. 4-8 November, Strasbourg, France. Abstract No O-15, p.58.
4. **Douni E**, Makrinou E, Kollias G. (2005). Genome wide analysis of sensitized ENU mutagenesis screens in animal models for arthritis and IBD, as a tool for drug target discovery. *Mutation detection workshop*. 31 May-4 June, Santorini.
5. **Douni E**, Armaka M, Makrinou E, Kollias G. (2006). Functional genetic and genomic analysis of modeled arthritis and osteoclastogenesis. *1st International Conference on Osteoimmunology: Interactions of the immune and skeletal systems*. Aegean Conferences, May28-June2, Crete. Aegean Conference Series vol.22, Abstract No5.
6. **Douni E**, Armaka M, Makrinou E, and Kollias G. (2006). Functional genetic and genomic analysis of modeled arthritis and other bone diseases. *16th European Congress of Immunology*. September 6-9, Paris. Abstract No SC55-770.
7. Beirnaert E, Lauwereys M, De Haard H, Casteels P, Jonckheere H, Spinelli S, Cambillau C, **Douni E**, Kollias G, Hoogenboom H, Dreier T. (2006). Superior efficacy of a format engineered anti-human TNFa nanobody in a transgenic mouse model (Tg197) of polyarthritis. *16th European Congress of Immunology*. September 6-9, Paris. Abstract No WD60-339.
8. Kranidioti K, Alexopoulou L, Kranidioti K, Xanthoulea S, Denis M, Kotanidou A, **Douni E**, Blackshear PJ, Kontoyiannis DL, Kollias G. (2006). Transmembrane TNF protects mutant mice against intracellular bacterial infections, chronic inflammation and autoimmunity. *1st International MUGEN Conference on animal models for human immunological disease*. September 10-13, Athens. Abstract No 27.
9. **Douni E**, Makrinou E, Giannakas N, Alexakos G, Kollias G. (2006). A sensitized ENU mutagenesis screen for genetic modifiers of Rheumatoid Arthritis and Inflammatory Bowel Disease. *1st International MUGEN Conference on animal models for human immunological disease*. September 10-13, Athens. Abstract No 44.
10. Sotsios Y, **Douni E**, Kollias G. (2006). TNF-driven animal models of inflammatory disease: effective tools for pre-clinical in vivo evaluation of pharmaceuticals. *1st International MUGEN Conference on animal models for human immunological disease*. September 10-13, Athens. Abstract No 52.
11. **Douni E**, Makrinou E, Kollias G. (2007). Identification of a novel loss-of-function missense mutation in the RANKL gene using ENU mutagenesis. *21st International Mouse Genome Conference*, 28 October-1 November, Kyoto Japan. Abstract No P108 p.144.
12. **Douni E**, Makrinou E, Mermelekas G, Giannakas N, Kollias G. (2007). Identification of genetic modifiers using random mutagenesis in Rheumatoid Arthritis and Inflammatory Bowel Disease. *21st International Mouse Genome Conference*, 28 October-1 November, Kyoto Japan. Abstract No P109 p.144.
13. **Douni E**, Makrinou E, Kollias G. (2008). Identification of a novel loss-of-function missense mutation in the RANKL gene that causes osteopetrosis in mice. *35th European Symposium on*

calcified tissues. 24-28 May, Barcelona Spain. Published in *Calcified Tissue International* vol 82, suppl. Abstract Mo-OP35 p.S57.

14. **Douni E**, Makrinou E, Zwerina J, Penninger JM, Schett G, Kollias G. (2008). Identification and characterization of a novel loss-of-function missense mutation in the RANKL gene that causes osteopetrosis in mice. *2nd International Conference on Osteoimmunology: Interactions of the immune and skeletal systems*. Aegean Conferences, June 8-13, Rhodes. Aegean Conference Series vol.35, Abstract No 62.
15. **Douni E**, Aidinis V, Kontoyiannis D, Graf D, Kollias G. (2009). Secondary immunological phenotyping using animal models for human inflammatory and autoimmune diseases: the MUGEN approach. *EUMODIC Annual Meeting*, March 2-4, Athens, Greece.
16. Niti A, Rinotas V, **Douni E**. (2009). A novel humanized RANKL transgenic mouse model of osteoporosis. *36th European Symposium on calcified tissues, 23-27 May, Vienna*. *Bone* vol44, no2 p.S423.
17. Ioakeimidis F, Rinotas V, Makrinou E, Kollias G, **Douni E**. (2009). Characterization of a novel mouse model of autosomal recessive neuromuscular disease and lymphoid hypoplasia generated by ENU mutagenesis [MUGEN fellowship]. *4th ENII-MUGEN Immunology Summer School*, 17-24 May, Capo Caccia, Sardinia.
18. Niti A, Rinotas V, **Douni E**. (2009). A novel genetic model of osteoporosis in transgenic mice expressing human RANKL. *2nd MUGEN Conference*, 8-10 October, Athens.
19. Ioakeimidis F, Karakostas A, Rinotas V, Makrinou E, Kollias G, **Douni E**. (2009). A novel ENU-induced mouse model of autosomal recessive neuromuscular disease and lymphoid abnormalities. *2nd MUGEN Conference*, 8-10 October, Athens.
20. Karakostas A, Ioakeimidis F, Rinotas V, Kollias G, **Douni E**. (2009). Identification of a new SLC25 member that causes autosomal recessive ataxia in ENU-mutagenized mice. *2nd MUGEN Conference*, 8-10 October, Athens.
21. **Douni E**, Aidinis V, Kontoyiannis D, Graf D, Kollias G. (2010). Secondary immunological phenotyping using animal models for human inflammatory and autoimmune diseases. *EUMODIC Annual Meeting*, March 25-26, Brussels.
22. Karakostas A, Ioakeimidis F, Rinotas V, Kollias G, **Douni E**. (2010). Identification and characterization of a novel SLC25 member that causes autosomal recessive ataxia in mice. *EUMODIC Annual Meeting*, March 25-26, Brussels.
23. Niti A, Dacquin R, Rinotas V, Jurdic P, **Douni E**. (2010). Generation and analysis of a novel genetic model of osteoporosis: Human RANKL-expressing transgenic mice. *3rd International Conference on Osteoimmunology: Interactions of the immune and skeletal systems*. Aegean Conferences, June 20-25, Santorini. Aegean Conference Series vol.49, Abstract No 65.
24. Ioakeimidis F, Rinotas V, Makrinou E, Kollias G, and **Douni E**. (2010). Identification of a novel member of the DnaJC family that causes neuromuscular disease in mice. *Neuroscience days of the Hellenic Society for Neuroscience*. 1-2 October, Athens.

25. Karakostas A, Ioakeimidis F, Rinotas V, Kollias G, **Douni E.** (2010). Identification of a novel SLC25 member that causes autosomal recessive ataxia in ENU-mutagenized mice. *Neuroscience days of the Hellenic Society for Neuroscience*. 1-2 October, Athens.
26. Ioakeimidis F, Rinotas V, Makrinou E, Kollias G, **Douni E.** (2010). A forward genetics approach identifies a novel member of the DnaJC family that causes neuromuscular disease in mice. *24th International Mammalian Genome Conference*. 17-21 October, Heraklion.
27. Karakostas A, Ioakeimidis F, Rinotas V, Kollias G, **Douni E.** (2010). Identification of a novel SLC25 member that causes autosomal recessive ataxia in ENU-mutagenized mice. *24th International Mammalian Genome Conference*. 17-21 October, Heraklion.
28. Niti A, Dacquin R, Rinotas V, Jurdic P, **Douni E.** (2010). A novel genetic model of osteoporosis by overexpression of human RANKL in transgenic mice. *24th International Mammalian Genome Conference*. 17-21 October, Heraklion.
29. Niti A, Dacquin R, Bonnet N, Rinotas V, Ferrari S, Jurdic P, **Douni E.** (2011). Novel genetic models of osteoporosis by overexpressing human RANKL in transgenic mice. *38th European Symposium on Calcified Tissues*, 7-11 May, Athens.
30. Ioakeimidis F, Rinotas V, Kollias G, **Douni E.** (2011). A novel member of the DNAJC family localized in mitochondria causes neuromuscular disease and immune abnormalities in mice. *Mitochondria dynamics: from mechanisms to disease*. 11-15 September, Sardinia.
31. Niti A, Dacquin R, Bonnet N, Rinotas V, Ferrari S, Jurdic P and **Douni E.** (2011). Novel genetic models of osteoporosis in transgenic mice overexpressing human RANKL. *Final EUMODIC meeting*, 21-22 November, Geneva.
32. Ioakeimidis F, Rinotas V, Kollias G, **Douni E.** (2011). A novel member of the DNAJC family causes neuromuscular disease and immune abnormalities in mice. *Final EUMODIC meeting*, 21-22 November, Geneva.
33. Ioakeimidis F, Rinotas V, Fasseas C, Kollias G and **Douni E.** (2012). An ENU Forward Genetics Approach in Mice Identifies a Role of a Novel Mitochondrial DnaJC Protein in Mitochondrial Structure and Proper Neuromuscular Function. *Mitochondria in life, death and disease, FEBS/EMBO course*, 9-13 May, Crete Greece. [Selected oral presentation].
34. Kano T, Karakostas A, Ioakeimidis F, Rinotas V, Kollias G, and **Douni E.** (2012). A Novel SLC25 Member of Mitochondrial Carriers Causes Autosomal Recessive Neurological Disease in Mice. *Mitochondria in life, death and disease, FEBS/EMBO course*, 9-13 May, Crete Greece.
35. Niti A, Dacquin R, Bonnet N, Rinotas V, Ferrari S, Jurdic P and **Douni E.** (2012). Modeling osteoporosis in transgenic mice overexpressing human RANKL. *4th International Conference on Osteoimmunology: Interactions of the immune and skeletal systems*. Aegean Conferences, June 18-21, Corfu Greece.
36. Rinotas V, Alexiou P, Papakyriakou T, Papaneophytou C, Kontopidis G, Couladouros E, Eliopoulos E, and **Douni E.** (2012). Development of novel therapeutic approaches targeting RANKL trimerization. *4th International Conference on Osteoimmunology: Interactions of the immune and skeletal systems*. Aegean Conferences, June 18-21, Corfu Greece.

37. Rinotas V, Dacquin R, Bonnet N, Ferrari S, Jurdic P, Alexiou P, Papakyriakou T, Papaneophytou C, Kontopidis G, Couladouros E, Eliopoulos E, **Douni E.** 2012. Study of RANKL-mediated pathogenic mechanisms in mouse models and development of new therapeutic approaches. *5th International Workshop on Advances in the Molecular Pharmacology and Therapeutics of Bone Disease*, 27-30 June Oxford, UK.
38. Violitzi F, Rinotas V, **Douni E.** (2012). Inhibition of BAFF trimerization with site-directed mutagenesis. *2nd Conference on Agricultural Biotechnology*, 4-5 October, Athens.
39. Terzenidou M, Kano T, Karakostas A, Ioakeimidis F, Kollias G, **Douni E.** (2012). Studying the pathogenic role of a novel SLC25 mitochondrial carrier in a genetic mouse model of neurological disease. *2nd Conference on Agricultural Biotechnology*, 4-5 October, Athens.
40. Rinotas V, Niti A, Kontopidis G, Couladouros E, Eliopoulos E, **Douni E.** (2012). Study of RANKL-mediated pathogenic mechanisms in mouse models and development of new therapeutic approaches. *2nd Conference on Agricultural Biotechnology*, 4-5 October, Athens.
41. Ioakeimidis F, Rinotas V, Fasseas C, Kollias G, **Douni E.** (2012). Identification of the role of DNAJC in mitochondrial structure and neuromuscular function in mice. *2nd Conference on Agricultural Biotechnology*, 4-5 October Athens.
42. Ioakeimidis F, Rinotas V, Fasseas C, Kollias G, **Douni E.** (2012). DnaJC11 is involved in mitochondrial cristae structure and neuromuscular disease in mice. *Neuroscience Days*, 2-3 November, Athens.
43. Terzenidou M, Kano T, Karakostas A, Ioakeimidis F, Kollias G, **Douni E.** (2012). A nonsense mutation in a novel SLC25 family gene of mitochondrial carriers causes severe recessive neurological disease in mice. *Neuroscience Days*, 2-3 November, Athens.
44. Terzenidou M, Kano T, Karakostas A, Ioakeimidis F, Kollias G, **Douni E.** (2013). A novel SLC25 mitochondrial carrier member causes autosomal recessive neurological disease in mice. *First Aegean Epilepsy Meeting*, 7-8 June, Heraklion, Crete, Greece.
45. Rinotas V, Violitzi F, Alexiou P, Liepouri F, Maranti A, Tsiliouka K, Strongilos A, Papakyriakou T, Papaneophytou C, Kontopidis G, Couladouros E, Eliopoulos E, **Douni E.** (2013). Novel SPD304-like inhibitors targeting trimerization of human RANKL. *5th International BBBB Conference "From Drug Discovery and Formulation Strategies to Pharmacokinetics-Pharmacodynamics"*, 26-28 September, Athens.
46. Rinotas V, Niti A, Dacquin R, Bonnet N, Ferrari S, Jurdic P, **Douni E.** (2013). Novel models of osteoporosis in transgenic mice overexpressing human RANKL. *ASBMR Annual Meeting*, 4-7 October, Baltimore, USA.
47. Rinotas V, Violitzi F, Alexiou P, Liepouri F, Maranti A, Tsiliouka K, Strongilos A, Papakyriakou T, Papaneophytou C, Kontopidis G, Couladouros E, Eliopoulos E, **Douni E.** (2013) Novel human RANKL inhibitors targeting its trimerization. *ASBMR Annual Meeting*, 4-7 October, Baltimore, USA.
48. Terzenidou M, Kano T, Karakostas A, Ioakeimidis F, Kollias G, **Douni E.** (2013). Identification of a novel SLC25 family member of mitochondrial carriers causing recessive neurological disease in

- mice. *26th Meeting of the Hellenic Neuroscience Society jointly with FP7 Regpot Neurosign*, 29 November - 1 December, Athens.
49. Rinotas V, Papadaki M, Dacquin R, Bonnet N, Jurdic P, Ferrari S, **Douni E.** (2013). Novel osteoporosis models by overexpressing human RANKL in transgenic mice. *64th Congress of the Hellenic Society of Biochemistry and Molecular Biology*, 6-8 December, Athens.
 50. Terzenidou M, Kano T, Karakostas A, Ioakeimidis F, Kollias G, **Douni E.** (2013). A novel SLC25 family member of mitochondrial carriers causes severe recessive neurological disease in mice. *64th Congress of the Hellenic Society of Biochemistry and Molecular Biology*, 6-8 December, Athens.
 51. Rinotas V, Violitzi F, Alexiou P, Liepouri F, Maranti A, Tsiliouka K, Strongilos A, Papakyriakou T, Papaneophytou C, Kontopidis G, Couladouros E, Eliopoulos E, **Douni E.** (2014) Novel small molecule inhibitors of human RANKL that target its trimerization. *5th International Conference on Osteoimmunology: Interactions of the Immune and Skeletal Systems*, 15-19 June, Kos Greece.
 52. Papadaki M, Rinotas V, **Douni E.** (2014). Osteoimmunological analysis in transgenic mice overexpressing human RANKL. *5th International Conference on Osteoimmunology: Interactions of the immune and skeletal systems*. Aegean Conferences, June 15-20, Kos, Greece.
 53. Ioakeimidis F, Violitzi F, Ott C, Kozjak-Pavlovic V, Rinotas V, Fasseas C, **Douni E.** (2014). A splicing mutation in the novel mitochondrial HSP40 co-chaperone DNAJC11 causes neuromuscular disease and lymphoid abnormalities in mice. *65th Congress of the Hellenic Society of Biochemistry and Molecular Biology*, 28-30 November, Thessaloniki, Greece. Abstract No 204.
 54. Terzenidou M, Segklia A, Kano T, Karakostas A, Violitzi F, Ioakeimidis F, Matsas R, Kollias, **Douni E.** (2014). A nonsense point mutation in a novel SLC25 family member of mitochondrial carriers causes severe recessive neurological disease and cerebellar pathology in mice. *65th Congress of the Hellenic Society of Biochemistry and Molecular Biology*, 28-30 November, Thessaloniki, Greece. Abstract No 205.
 55. Papadaki M, Rinotas V, Kollias G, **Douni E.** (2014). Osteoimmunological interactions in transgenic mice overexpressing human RANKL. *65th Congress of the Hellenic Society of Biochemistry and Molecular Biology*, 28-30 November, Thessaloniki, Greece. Abstract No O13.
 56. Violitzi F, Samiotaki M, Ioakeimidis F, Boyongo M, Panayotou G, **Douni E.** (2014). Understanding the physiological role of DNAJC11 through identification of its interactors. *65th Congress of the Hellenic Society of Biochemistry and Molecular Biology*, 28-30 November, Thessaloniki, Greece. Abstract No O16.
 57. Kano T, Rokidi S, Remboutsika E, Mouzakis D, Zaoutsos S, Bouropoulos N, **Douni E.** (2015). Mechanical stress analysis and osteoblastic induction on calcium phosphate-hydroxyapatite cements. *4th Joint Meeting of the ECTS and IBMS*, 25-28 April, Rotterdam, The Netherlands.
 58. Papadaki M, Rinotas V, Kollias G, **Douni E.** (2015). Analysis of Osteoimmune Interactions in Transgenic Mice Overexpressing Human RANKL. *4th Joint Meeting of the ECTS and IBMS*, 25-28 April 2015, Rotterdam, The Netherlands.
 59. Rinotas V, Chalkidi N, Violitzi F, Alexiou P, Liepouri F, Maranti A, Tsiliouka K, Strongilos A, Papakyriakou T, Papaneophytou C, Kontopidis G, Couladouros E, Eliopoulos E, **Douni E.** (2015). Novel small molecule inhibitors of human RANKL. *4th Joint Meeting of the ECTS and IBMS*, 25-28 April, Rotterdam, The Netherlands.

60. Segklia A, Terzenidou M, Papastefanaki F, **Douni E**, Matsas R. (2015). A nonsense point mutation in a novel SLC25 family member of mitochondrial carriers causes severe recessive neurological disease and epilepsy in mice. XII European Meeting on Glial Cells in Health and Disease, 15-18 July, Bilbao, Spain.
61. Rinotas V, Papadaki M, **Douni E**. (2015). RANKL overexpression in transgenic mice leads to trabecular bone loss, cortical porosity and bone marrow adiposity. *1st Bone Marrow Adiposity Meeting*, 28-29 August, Lille, France.
62. Kano T, Rokidi S, Remboutsika E, Mouzakis D, Zaoutsos S, Bouropoulos N, **Douni E**. (2015). Phosphate-Hydroxyapatite Cements: Mechanical Stress Analysis and Osteoblastic Induction. *27th European Conference on Biomaterials*, 30 August - 3 September, Krakow, Poland.
63. Terzenidou M, Segklia A, Kano T, Karakostas A, Violitzi F, Ioakeimidis F, Kollias G, Matsas R, **Douni E**. (2015). A nonsense point mutation in a novel SLC25 family member of mitochondrial carriers causes severe recessive neurological pathology in mice. *FEBS/EMBO Course: Mitochondria in Life, Disease and Death*, 12-15 October, Heraklion, Crete, Greece. Abstract No 49R.
64. Violitzi F, Samiotaki M, Ioakeimidis F, Panayotou G, **Douni E**. (2015). Investigating the function of the novel mitochondrial HSP40 co-chaperone DNAJC11 through domain characterization and identification of its interactors. *FEBS/EMBO Course: Mitochondria in Life, Disease and Death*, 12-15 October, Heraklion, Crete, Greece. Abstract No 64G.
65. Ioakeimidis F, Violitzi F, Rinotas V, Gialitaki E, Ott C, Kozjak-Pavlovic V, Fasseas C, **Douni E**. (2015). A splicing mutation in the novel mitochondrial HSP40 co-chaperone DNAJC11 causes motor neuron pathology and cristae disorganization mice. *FEBS/EMBO Course: Mitochondria in Life, Disease and Death*, 12-15 October, Heraklion, Crete, Greece. Abstract No 12G.
66. Charalambous M, Papastefanaki F, Terzenidou M, **Douni E**, Matsas R. (2015). The pathophysiological role of a novel SLC25 family member in the spinal cord and sciatic nerve of mutant mice. *66th Congress of the Hellenic Society of Biochemistry and Molecular Biology*, 11-13 December, Athens, Greece.
67. Terzenidou M, Segklia A, Kano T, Karakostas A, Violitzi V, Ioakeimidis F, Kollias G, Matsas R, **Douni E**. (2015). Identification of a novel SLC25 family member causing severe recessive neurological pathology in mice. *66th Congress of the Hellenic Society of Biochemistry and Molecular Biology*, 11-13 December, Athens, Greece.
68. Rinotas V, Violitzi F, Alexiou P, Liepouri F, Maranti A, Tsiliouka K, Strongilos A, Papakyriakou T, Papanephytous C, Kontopidis G, Couladouros E, Eliopoulos E, **Douni E**. (2015). Identification of small molecule inhibitors of RANKL as novel antiresorptive agents in osteoporosis. *66th Congress of the Hellenic Society of Biochemistry and Molecular Biology*, 11-13 December, Athens, Greece.
69. Papadaki M, Rinotas V, Plestilova L, Kollias G, Jüngel A, **Douni E**. (2015). Expression profile and osteoimmunological interactions in osteoporotic transgenic mice overexpressing human RANKL. *66th Congress of the Hellenic Society of Biochemistry and Molecular Biology*, 11-13 December, Athens, Greece.
70. Violitzi F, Samiotaki M, Ioakeimidis F, Rinotas V, Panayotou G, **Douni E**. (2015). Domain characterization and identification of protein interactors of the novel mitochondrial DNAJC11 protein that causes a neuromuscular phenotype in mice. *66th Congress of the Hellenic Society of Biochemistry and Molecular Biology*, 11-13 December, Athens, Greece.
71. Papadaki M, Rinotas V, Plestilova L, Kollias G, Jüngel A, **Douni E**. (2016). Osteoimmunological interactions and expression profile in osteoporotic transgenic mice overexpressing human RANKL. *6th International Conference on Osteoimmunology: Interactions of the immune and skeletal systems*. Aegean Conferences, June 17-22, Chania, Greece.

72. Rinotas V, Papadaki M, **Douni E.** (2016). Bone marrow adipogenesis in transgenic mice expressing human RANKL. *6th International Conference on Osteoimmunology: Interactions of the immune and skeletal systems*. Aegean Conferences, June 17-22, Chania, Greece.
73. Rinotas V, Siniorakis E, Papadaki M, **Douni E.** (2016). Analysis of bone marrow adiposity in human RANKL-expressing transgenic mouse models of osteoporosis. *2nd Bone Marrow Adiposity Meeting*, August 25-26, Rotterdam, the Netherlands.
74. Rinotas V, Kontou A, Siniorakis E, Papadaki M, **Douni E.** (2017). Bone Marrow Adiposity in TgRANKL Osteoporosis Mouse Models. *3rd Bone Marrow Adiposity Meeting*, 31 August - 1 September, Lausanne, Switzerland.
75. Kano T, Rinotas V, Rokidi S, Mouzakis D, Zaoutsos S, Bouropoulos N, **Douni E.** (2017). Phosphate-Hydroxyapatite Cements: Porosity Related Mechanical Response And Osteoblastic Induction Behavior. *28th European Conference on Biomaterials*, 4-8 September, Athens, Greece.
76. Lygizos I, Terzenidou M, Samiotaki M, Violitzi F, Panayotou G, **Douni E.** (2017). Studying SLC25A46-mediated pathogenic mechanisms in a genetic mouse model of neuropathology with proteomic analysis. *68th Congress of the Hellenic Society of Biochemistry and Molecular Biology*, 10-12 November, Athens, Greece.
77. Violitzi F, Samiotaki M, Perivolidi V, Rinotas V, Grivas I, Markogiannaki M, Haralambous S, Panayotou G, **Douni E.** (2017). Understanding DNAJC11-mediated neuromuscular pathology through identification of its protein interactors with proteomic analysis. *68th Congress of the Hellenic Society of Biochemistry and Molecular Biology*, 10-12 November, Athens, Greece.
78. Rinotas V, Kontou A, Tzortzis E, Siatra P, Kolokotroni A, Siniorakis E, Papadaki M, **Douni E.** (2017). Investigating bone marrow adiposity in TgRANKL osteoporosis mouse models. *68th Congress of the Hellenic Society of Biochemistry and Molecular Biology*, 10-12 November, Athens, Greece.
79. Papadaki M, Rinotas V, Stavropoulos D, Bakogiannis V, Kollias G, **Douni E.** (2017). RANKL, a novel disease modifier in inflammatory arthritis. *68th Congress of the Hellenic Society of Biochemistry and Molecular Biology*, 10-12 November, Athens, Greece.
80. Kolokotroni A, Rinotas V, Giakountis A, Papadaki M, Hatzis P, Plestilova L, Jüngel A, **Douni E.** (2017). Investigating the pathophysiological role of RANKL in bone and mammary gland. *68th Congress of the Hellenic Society of Biochemistry and Molecular Biology*, 10-12 November, Athens, Greece.
81. Rinotas V, Tzortzis E, Siatra P, Kolokotroni A, Papadaki M, **Douni E.** (2018). Bone marrow adipose tissue (BMAT) in modeled osteoporosis. *7th International Conference on Osteoimmunology: Interactions of the immune and skeletal systems*. Aegean Conferences, 3-8 June, Chania, Greece.
82. Papadaki M, Rinotas V, Violitzi F, Samiotaki M, Panayotou G, **Douni E.** (2018). RANKL, a disease modifier in inflammatory arthritis. *7th International Conference on Osteoimmunology: Interactions of the immune and skeletal systems*. Aegean Conferences, June 3-8, Chania, Greece.
83. Rinotas V, Tzortzis E, Siatra P, Kritikos K, Nikolaou P, Kolokotroni A, Papadaki M, **Douni E.** (2018). Bone Marrow Adiposity in modeled osteoporosis. *4th Bone Marrow Adiposity Meeting*, 29-31 August, Lille, France.
84. Kolokotroni A, Rinotas V, Gkikopoulou E, **Douni E.** (2018). Investigating the pathophysiological role of RANKL in mammary gland development. *69th Congress of the Hellenic Society of Biochemistry and Molecular Biology*, 23-25 November, Larissa, Greece.
85. Rinotas V, Tzortzis E, Siatra P, Kritikos K, Nikolaou P, Kolokotroni A, Papadaki M, **Douni E.** (2018). Bone Marrow Adiposity in RANKL-mediated modeled osteoporosis. *69th Congress of the Hellenic Society of Biochemistry and Molecular Biology*, 23-25 November, Larissa, Greece.

86. Violitzi F, Samiotaki M, Perivolidi VI, Thireou T, Rinotas V, Grivas I, Markogiannaki M, Haralambous S, Panayotou G, **Douni E.** (2018). Studying the role of mitochondrial protein DNAJC11 in the induction of a neuromuscular phenotype in mice. 11th Congress of the Hellenic Society of Bioscientists, 13-15 December, Athens, Greece.
87. Kolokotroni A, Rinotas V, Gkikopoulou E, **Douni E.** (2019). RANKL and mammary gland pathophysiology in modeled osteoporosis. *46th European Calcified Tissue Society Congress*, 11-14 May, Budapest, Hungary.
88. Papadaki M, Rinotas V, Violitzi F, Thireou T, Samiotaki M, Panayotou G, **Douni E.** (2019). New role for RANKL as a proinflammatory modulator in modeled inflammatory arthritis. *46th European Calcified Tissue Society Congress*, 11-14 May, Budapest, Hungary.
89. Rinotas V, Tzortzis E, Siatra P, Kritikos K, Nikolaou P, Papadaki M, **Douni E.** (2019). Correlation between bone marrow adiposity and bone resorption in modeled osteoporosis. *46th European Calcified Tissue Society Congress*, 11-14 May, Budapest, Hungary.
90. Pantelidou P, Rinotas V, Papadopoulos A, Efstathiopoulos E, Mouzakis D, Bakirtzi K, Douni E. (2019). Investigating the Role of Exosomes in Modeled Osteoporosis. *30th Annual Conference of the European Society for Biomaterials*, 9-13 September, Dresden, Germany.
91. Kolokotroni A, Rinotas V, Gkikopoulou E, Dermitzaki E, Efstathiou E, Rentis T, Samiotaki M, Panayotou G, **Douni E.** (2019). Mammary gland development in TgRANKL mouse models of osteoporosis. *Joint Meeting of the Hellenic Society for the Study of Bone Metabolism and the Dutch Society for Calcium and Bone Metabolism*, 10-12 October 2019, Athens, Greece.
92. Rinotas V, Kritikos K, Nikolaou P, Papadopoulos A, Kolokotroni A, **Douni E.** (2019). Increased bone marrow adiposity and bone resorption in humanized RANKL transgenic mouse models of osteoporosis. *Joint Meeting of the Hellenic Society for the Study of Bone Metabolism and the Dutch Society for Calcium and Bone Metabolism*, 10-12 October 2019, Athens, Greece.
93. Kolokotroni A, Rinotas V, Gkikopoulou E, Ntari L, Dermitzaki E, Efstathiou E, Rentis A, Zareifi D, Samiotaki M, Panayotou G, Lymperopoulos I, Alexopoulos L, Denis M, Karagianni N, **Douni E.** (2019). Investigating the pathophysiological role of RANKL in mammary gland development and carcinogenesis. *70th Congress of the Hellenic Society of Biochemistry and Molecular Biology*, 29 November - 1 December, Athens, Greece.
94. Perivolidi VI, Ntounias I, Stavrou A, Violitzi F, Samiotaki M, Panayotou G, **Douni E.** (2019). Characterization of SLC25A46 missense mutations identified in patients with neurodegenerative disorders. *70th Congress of the Hellenic Society of Biochemistry and Molecular Biology*, 29 November - 1 December, Athens, Greece.
95. Rinotas V, Papadopoulos A, Kritikos K, Samiotaki M, Panayotou G, **Douni E.** (2019). Mechanisms driving bone marrow adiposity in modeled osteoporosis. *70th Congress of the Hellenic Society of Biochemistry and Molecular Biology*, 29 November - 1 December, Athens, Greece.
96. Rinotas V, Kritikos K, Papadopoulos A, **Douni E.** (2020). Interplay between Bone Marrow Adiposity and bone loss in TgRANKL osteoporotic models. *6th International Meeting on Bone Marrow Adiposity*, 9-10 September, Seattle, Washington, USA (Virtual meeting).
97. Ntari L, Christodoulou-Vafeiadou E, Kolokotroni A, Papanastasiou A, Rouchota M, Loudos G, **Douni E.**, Denis M, Karagianni, N. (2020). Development of a human RANKL-driven model of mammary carcinogenesis. *Infrafrontier Conference 2020 "Targeting cancer with animal models"*, 7-8 October 2020 (Virtual Conference).

98. Kolokotroni A, Rinotas V, Gkikopoulou E, Efstathiou E, Dermitzaki E, Rentis T, Zareifi D, Lymperopoulos I, Samiotaki M, Alexopoulos L, Panayotou G, **Douni E.** (2020). RANKL promotes the expansion of mammary epithelial cells in osteoporotic TgRANKL mouse models. *47th European Calcified Tissue Society Congress, 22-24 October (Digital Congress).*
99. Kolokotroni A, Rinotas V, Gkikopoulou E, Ntari L, Rouchota M, Fragogeorgi E, Zareifi D, Fotis C, Lymperopoulos I, Alexopoulos L, Loudos G, Denis M, Karagianni N, **Douni E.** (2020). Establishment of progesterone-induced mammary carcinogenesis in a humanized TgRANKL osteoporotic mouse model. *47th European Calcified Tissue Society Congress, 22-24 October (Digital Congress).*
100. Rinotas V, Nikolaou P, Kritikos K, Papadopoulos A, Plestilova L, Jungel A, Samiotaki M, Panayotou G, **Douni E.** (2020). Bone remodeling mechanisms in osteoporotic TgRANKL transgenic mouse models. *47th European Calcified Tissue Society Congress, 22-24 October (Digital Congress).*
101. Perivolidi VI, Violitzi F, Panagiotou G, **Douni E.** (2020). Bone resorption in mouse models of mitochondrial neurological diseases. *47th European Calcified Tissue Society Congress, 22-24 October (Digital Congress).*
-

12. Invited Speaker (from 2004)

- 2004.** "Transgenic and knockout systems in Immunology". Hellenic Society of Immunology. Seminar in Immunology 20th cycle. 25 January, Athens, Greece.
- 2004.** "Random mutagenesis in animal models of human immunological diseases for the discovery of new therapeutic targets". Hellenic Conference of Immunology. 8-11 December, Thessaloniki, Greece.
- 2005.** "Anti-TNF and anti-IL-1 therapies: from mouse to human". Hellenic Conference of Pathology. 11-14 October, Athens, Greece.
- 2006.** "Identification of disease targets using random ENU mutagenesis in animal models". 3rd International Biotechnological Conference. 5-7 October, Athens, Greece.
- 2006.** "Novel approaches studying inflammation". 19th Hellenic Rheumatology Conference., 29 Nov.-2 Dec., Athens, Greece.
- 2006.** "Random ENU Mutagenesis". MUGEN Transgenesis Gene Targeted Mutagenesis Course. April 10-13, Athens, Greece.
- 2007.** "ENU Mutagenesis". 1st International Course on Laboratory Animal Science. 24 September-5 October, Athens, Greece.
- 2007.** "Molecular Biology and genetically modified animal models". 1st Hellenic Seminar of Experimental Biomedical Research. 11-14 December, Athens, Greece.
- 2008.** "Identification and characterization of a novel loss-of-function missense mutation in the RANKL gene that causes osteopetrosis in mice". Institut de Génomique Fonctionnelle de Lyon, 6 May Lyon, France.
- 2008.** "Functional Genomics for the understanding of pathophysiology in animal models". 14th Scientific Conference of Greek Medical School Students. 9-11 May, Athens, Greece.

- 2008.** “Chronic inflammatory disease mechanisms and development of therapies”. 28th European Section Meeting of the International Society for Heart Research. 28-31 May, Athens, Greece.
- 2008.** “Forward Genetics”. 2nd International Course on Laboratory Animal Science. 22 September-3 October, Athens, Greece.
- 2008.** “The osteoblast, the osteoclast and osteoporosis”. 64th Hellenic Orthopedic Conference. Round table: Osteoporosis today. 8-11 October, Athens, Greece.
- 2008.** “Functional genomics to understand pathophysiology in animal models”. 27th Congress of the International Academy of Pathology. 12-17 October, Athens, Greece.
- 2008.** “Genetically modified animal models in Osteoimmunology”. 2nd Hellenic Seminar of Experimental Biomedical Research. 20-22 November, Athens, Greece.
- 2009.** “Forward genetics: a tool for the discovery of novel disease targets in Immunology”. 2nd Immunology Summer School & Conference, 31 August-4 September, Kefalonia, Greece.
- 2009.** “Forward Genetics as a tool for the identification of novel disease targets”. Medical School, University of Crete, 6 July, Heraklion, Greece.
- 2009.** “Genetic Standardization”. 3rd International Course on Laboratory Animal Science. 21 September-2 October, Athens, Greece.
- 2009.** “Forward Genetics”. 3rd International Course on Laboratory Animal Science. 21 September-2 October, Athens, Greece.
- 2009.** “Forward and Reverse Genetics”. Workshop on Mouse Immune Phenotyping. 6-8 October, Athens, Greece.
- 2009.** “Functional Genetics technologies in animal models”. 1st Hellenic Conference of Agricultural Biotechnology, 16-18 October, Athens, Greece.
- 2009.** “Forward Genetics as a tool for the identification of novel disease targets”. Institute of Biology. N.C.S.R. Demokritos, 5 November, Athens, Greece.
- 2010.** “The role of RANKL in osteoimmunology and development of therapies in transgenic mice”. Psoriasis and Arthritides, update and new perspectives. 23-24 January, Heraklion, Greece.
- 2010.** “Transgenic mice overexpressing RANKL as a model of osteoporosis”. 18th Hellenic Conference of Hellenic Society of Studying Bone Metabolism. Round table: Experimental models of Osteoporosis. 14-16 May, Athens, Greece.
- 2010.** “Genetic Standardization”. 4th International Course on Laboratory Animal Science. 4-15 October, Athens, Greece
- 2010.** “Forward Genetics”. 4th International Course on Laboratory Animal Science. 4-15 October, Athens, Greece.
- 2011.** “Osteoimmunology-Mouse models of immune diseases”. 3rd Immunology Summer School, 27June-1 July, Spetses, Greece.

- 2011.** "Genetic Standardization". 5th *International Course on Laboratory Animal Science*. 16-30 September, Athens, Greece.
- 2011.** "Forward Genetics". 5th *International Course on Laboratory Animal Science*. 16-30 September, Athens, Greece.
- 2011.** "Modelling RANKL-mediated pathologies in mice". Final EUMODIC meeting, 21-22 November, Geneva, Switzerland.
- 2011.** "Studying RANKL-mediated pathologies in transgenic mice". Geneva University Hospital, 22 November, Geneva, Switzerland.
- 2011.** "Studying the pathogenic role of RANKL in transgenic mice overexpressing human RANKL". 2nd Hellenic Symposium of Research Dermatology. 30 September-2 October, Heraklion, Greece.
- 2012.** Functional Genetics technologies in animal models. 2nd *Conference on Agricultural Biotechnology*, 4-5 October Athens.
- 2013.** "Functional genomics in the mouse: modeling human diseases". Medical School, University of Patras, 12 March, Patras, Greece.
- 2014.** Novel therapeutic approaches in osteoporosis through RANKL inhibition. 5th *International BBBB Conference "From Drug Discovery and Formulation Strategies to Pharmacokinetics-Pharmacodynamics"*, 26-28 September, Athens.
- 2014.** "RANKL-mediated pathologies and novel therapeutic approaches in modeled osteoporosis". 2nd Autumn School "Techniques in Immunology and Bone Biology" of OSTEOIMMUNE ITN, 2-3 September, Berlin, Germany.
- 2015.** "Identification of novel pathogenic targets in mice through Forward Genetics". Laboratory Animals in Biomedical Research: Theory and practice, 18-22 May, Athens, Greece.
- 2015.** "Identification of novel causative genes for bone and neurological diseases through Functional Genetics approaches in mice". 37th Annual Conference of Hellenic Society for Biological Sciences, 21-23 May, Volos, Greece.
- 2015.** "Identification of small molecule inhibitors of RANKL as novel antiresorptive agents in osteoporosis". 1st International Congress of Controlled Release Society: Small molecules and Biotechnological drugs, 27-28 May, Athens, Greece.
- 2015.** "Genetically altered mouse models of bone and neurological diseases for the identification of novel disease targets". LAS EU Functions Course, 9-17 November 2015, Athens, Greece.
- 2016.** "Genetically altered mouse models of bone and neurological diseases for the identification of novel disease targets". LAS EU Functions Course, 12-21 September 2016, Athens, Greece.
- 2016.** "Modeling osteoporosis in transgenic mice expressing human RANKL". 4th BTCure annual workshop on animal models. 18-20 September 2016, Athens, Greece.
- 2017.** "Biological properties of Phosphate-Hydroxyapatite cements". 27th Interdisciplinary Research Conference on injectable Biomaterials and interventional procedures. 18-21 May, Athens, Greece.
- 2017.** "Identification of novel pathogenic targets in mice through Forward Genetics". TT-RIIP International course "Transgenic technologies in modeling human diseases: Principles, associated technologies, animal management and ethics". 5-13 June, Hellenic Psteur Institute, Athens, Greece.

- 2017.** "Investigation of pathogenic mechanisms in osteoporosis and neurodegenerative diseases through modeling of human diseases in mice". 5th Hellenic forum for Science Technology and Innovation. 5-7 July, Demokritos, Athens, Greece.
- 2017.** "Genetically altered mouse models of bone and neurological diseases for the identification of novel disease targets". 3rd LAS EU Functions Course, 2-11 October, Athens, Greece.
- 2017.** "Forward Genetics: from phenotype to genotype". Workshop on Transgenic animal models. 9 December 2017, Athens, Greece.
- 2017.** "Molecular tools for the genome modification with CRISPR/CAS9, a revolution in transgenesis" Workshop on Transgenic animal models. 9 December 2017, Athens, Greece.
- 2018.** "Genetically altered mouse models of bone and neurological diseases for the identification of novel disease targets". 4th LAS EU Functions Course, 1-11 October, Athens, Greece.
- 2019.** "Novel insights into the pathogenesis of modeled osteoporosis and mitochondrial neuropathies". 1st Scientific Retreat of B.S.R.C. "Alexander Fleming", 8-9 April 2019, Eretria, Greece.
- 2019.** "Applied Genetics for Bone Regeneration". Symposium and Course on "Infected Bone Loss Treatment As a Means of Scientific Improvisation, Innovation and Creativity", 11 May, Athens, Greece.
- 2019.** "Transgenesis and Humanized mouse models". 4th Congress on Gene therapy and Regenerative Medicine, 17-18 May, Athens, Greece.
- 2019.** "Genetically altered mouse models of bone and neurological diseases for the identification of novel disease targets". 5th LAS EU Functions Course, 1-11 October, Athens, Greece.
- 2019.** "From mouse models to humans: the RANKL paradigm". Joint meeting of the Hellenic Society for the Study of Bone Metabolism and the Dutch Society for Calcium and Bone Metabolism, 10-12 October, Athens, Greece.
- 2020.** "Modeling osteoporosis in humanized TgRANKL transgenic mice". 3rd International Congress on Pharmacogenomics and Personalized Diagnosis and Therapy. 10-12 January, Athens, Greece.
- 2020.** "Unravelling the molecular basis of human diseases through mouse genetic models". 11th Health Expo Athens/ 3rd Workshop of Hellenic Society of Nanotechnology in Health Sciences. 8-9 February, Athens, Greece.
-

13. Other activities

- 2007 Co-founder of Biomedcode Hellas, a Fleming spin-off for preclinical evaluation studies and novel drug development.